BioRestorative Therapies (BRTX) has released an update to notify the public and investors about a regulation fd disclosure.
BioRestorative Therapies, Inc. announced that it will present preliminary data from its Phase 2 clinical trial of BRTX-100 for chronic lumbar disc disease at the ORS 2024 Annual Meeting. Additionally, the Company will host a webcast and conference call to review the BRTX-100 poster on February 5, 2024. The press release detailing these events is provided for informational purposes and will not be considered part of any registration statement under the Securities Act of 1933.
For further insights into BRTX stock, check out TipRanks’ Stock Analysis page.
For a comprehensive understanding of the announcement, you can read the full document here.
